TP53 and intrahepatic cholangiocarcinoma: For ICC patients, the prevalence of TP53 (35.6% vs. 16.8%, p = 0.012) and KRAS (22.2% vs. 6.5%, p = 0.004) in our cohort was significantly higher than that in the MSKCC cohort, whereas the frequency of IDH1 (11.1% vs. 29.0%, p = 0.018) alteration was significantly lower (Figure 4B).